A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
NCT ID: NCT05923099
Last Updated: 2025-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
262 participants
INTERVENTIONAL
2023-09-20
2025-04-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The trial will last up to 36 weeks, including a screening/washout period (up to 4 weeks), a treatment period (16 weeks), and a follow up period (16 weeks). The participants will visit the clinic 17 times. For the first 4 weeks of the treatment period, participants will visit the clinic every week. For the next 12 weeks of the treatment period, participants will visit the clinic every 2 weeks. For the 16 week follow up period, participants will visit the clinic every 4 weeks.
The treatments will be given to the participants by staff at the clinic. They are given as an injection just under the skin.
At each visit the doctor will check the participants atopic dermatitis and if they have had any side effects. Participants will also complete an electronic diary every day about their atopic dermatitis and quality of life.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.
NCT04922021
Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis
NCT03514511
A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD
NCT05470114
A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects
NCT05099133
Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis
NCT05117060
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose regimen 1
Dose A every week from Week 0 to Week 3, then every 2 weeks from Week 4 to Week 16
LEO 138559
LEO 138559 given by injection just under the skin
Dose regimen 2
Dose B every week from Week 0 to Week 3, then every 2 weeks from Week 4 to Week 16
LEO 138559
LEO 138559 given by injection just under the skin
Dose regimen 3
Dose A every week from Week 0 to Week 3, then dose C every 2 weeks from Week 4 to Week 16
LEO 138559
LEO 138559 given by injection just under the skin
Dose regimen 4
Dose C every week from Week 0 to Week 3, then dose D every 2 weeks from Week 4 to Week 16
LEO 138559
LEO 138559 given by injection just under the skin
Placebo regimen
Placebo every week from Week 0 to Week 3, then every 2 weeks from Week 4 to Week 16
Placebo
Placebo given by injection just under the skin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LEO 138559
LEO 138559 given by injection just under the skin
Placebo
Placebo given by injection just under the skin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-75 years old (both included) at screening (Visit 1).
* Willingness to comply with the clinical trial protocol.
* At screening, diagnosis of atopic dermatitis (AD) as defined by the Hanifin and Rajka (1980) criteria for AD.
* History of AD for ≥1 year.
* Subjects who have a recent history (within 12 months before screening) with documented inadequate response to treatment with topical corticosteroid(s) (TCS) (±topical calcineurin inhibitor(s) (TCI) as appropriate) or for whom these topical AD treatments are medically inadvisable (e.g. due to important side effects or safety risks).
* Eczema Area and Severity Index (EASI) score ≥12 at screening and ≥16 at baseline.
* validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) score ≥3 at screening and baseline.
* Body Surface Area (BSA) of AD involvement ≥10% at screening and baseline.
* Atopic Dermatitis Symptom Diary (ADSD) Worst Itch score (weekly average) ≥4 at baseline.
* A woman of childbearing potential must use a highly effective form of birth control throughout the trial and for at least 18 weeks after last administration of IMP.
Exclusion Criteria
* Active dermatologic condition that could confound the diagnosis of AD or interfere with assessment of the treatment (e.g. scabies, contact dermatitis, rosacea, urticaria, or psoriasis).
* History of cancer, with the following exceptions:
* Subjects who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible provided that the subject is in remission and curative therapy was completed at least 12 months prior to screening.
* Subjects who have had other malignancies are eligible provided that the subject is in remission and curative therapy was completed at least 5 years prior to screening
* History of or current immunodeficiency syndrome.
* History of anaphylaxis following any biologic therapy.
* History of clinically significant infection within 4 weeks prior to baseline which, in the opinion of the investigator, may compromise the safety of the subject in the trial, interfere with evaluation of the IMP, or reduce the subject's ability to participate in the trial.
* Skin infection within 7 days prior to baseline
* Positive HBsAg or positive anti-HCV AND positive HCV RNA at screening.
* History of HIV infection or positive HIV serology at screening.
* Evidence of active or latent tuberculosis according to local standard of care for patients requiring initiation of a biologic treatment.
* ALT or AST level ≥2.0 times the ULN at screening.
* History of attempted suicide or is at significant risk of suicide (either in the opinion of the investigator or defined as a "yes" to suicidal ideation questions no. 4 or 5 or answering "yes" to suicidal behavior on the C-SSRS Screening version).
* Known or suspected hypersensitivity to any component(s) of the IMP.
* Any disorder at screening and/or baseline, which is not stable in the opinion of the investigator, and could:
* Affect the safety of the subject throughout the trial.
* Influence the results of the trial.
* Impede the subject's ability to complete the trial.
* Any significant abnormal finding at screening and/or baseline which may, in the opinion of the investigator:
* Put the subject at risk because of their participation in the trial.
* Influence the results of the trial.
* Influence the subject's ability to complete the trial.
* Current or recent chronic alcohol or drug abuse, or any other condition associated with poor compliance as judged by the investigator.
* Women who are pregnant or breastfeeding.
* Previous treatment with LEO 138559.
* Previous exposure to fezakinumab (anti-IL-22 Ab).
* Systemic treatment with immunosuppressive drugs, immunomodulating drugs, retinoids, corticosteroids (steroid eyedrops and inhaled or intranasal steroids are allowed), or JAK inhibitors within 28 days or 5 half-lives prior to baseline, whichever is longer.
* Use of tanning beds or phototherapy, within 4 weeks prior to baseline.
* Receipt of blood products within 28 days prior to screening.
* Treatment with:
* Any marketed or investigational biologic agents within 3 months or 5 half-lives, whichever is longer, prior to baseline.
* Any cell-depleting agents including but not limited to rituximab: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.
* Treatment with TCS, TCI, topical PDE-4 inhibitors, topical JAK inhibitors, or other medicated topical treatments within 7 days prior to baseline.
* Receipt of live attenuated vaccines 30 days prior to baseline.
* Treatment with any non-marketed drug substance (that is, an agent which has not yet been made available for clinical use following registration) within the last 4 weeks or 5 half lives prior to randomization, whichever is longer.
* Current participation in any other interventional clinical trial.
* Previously randomized in this clinical trial.
* Employees of the trial site, or any other individuals directly involved with the planning or conduct of the trial, or immediate family members of such individuals.
* Subjects who are legally institutionalized.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LEO Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Expert
Role: STUDY_DIRECTOR
LEO Pharma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
LEO Investigational Site
Fountain Valley, California, United States
LEO Investigational Site
Los Angeles, California, United States
LEO Investigational Site
San Francisco, California, United States
LEO Investigational Site
Hialeah, Florida, United States
LEO investigational site
Indianapolis, Indiana, United States
LEO investigational Site
New Albany, Indiana, United States
LEO Investigational Site
Ann Arbor, Michigan, United States
LEO Investigational Site
New York, New York, United States
LEO Investigational Site
Raleigh, North Carolina, United States
LEO Investigational Site
Cincinnati, Ohio, United States
LEO Investigational Site
Mayfield Heights, Ohio, United States
LEO Investigational Site
North Charleston, South Carolina, United States
LEO Investigational Site
Edmonton, Albana, Canada
LEO Investigational Site
Calgary, Alberta, Canada
LEO Investigational Site
Calgary, Alberta, Canada
LEO Investigational Site
Edmonton, Alberta, Canada
LEO Investigational Site
Surrey, British Columbia, Canada
LEO Investigational Site
Mississauga, Ontario, Canada
LEO Investigational Site
Sherbrooke, Quebec, Canada
LEO Investigational Site
Verdun, Quebec, Canada
LEO Investigational Site
Náchod, , Czechia
LEO Investigatonal Site
Ostrava-Poruba, , Czechia
LEO Investigational Site
Prague, , Czechia
LEO Investigational Site
Prague, , Czechia
LEO Investigational Site
Martigues, Bouches-du-Rhône, France
LEO Investigational Site
Dijon, , France
LEO Investigational Site
Nice, , France
LEO Investigational Site
Paris, , France
LEO Investigational Site
Rouen, , France
LEO Investigational Site
Augsburg, , Germany
LEO Investigational Site
Bad Bentheim, , Germany
LEO Investigational Site
Berlin, , Germany
LEO Investigational Site
Dresden, , Germany
LEO Investigational Site
Frankfurt am Main, , Germany
LEO Investigational Site
Freiburg im Breisgau, , Germany
LEO Investigational Site
Gera, , Germany
LEO Investigational Site
Kiel, , Germany
LEO Investigational Site
Leipzig, , Germany
LEO Investigational Site
Mahlow, , Germany
LEO Investigational Site
Münster, , Germany
LEO Investigational Site
Debrecen, , Hungary
LEO Investigational Site
Pécs, , Hungary
LEO Investigational Site
Szeged, , Hungary
LEO Investigational Site
Fukuoka, Fukuoka, Japan
LEO Investigational Site
Kobe, Hyōgo, Japan
LEO Investigational Site
Yokohama, Kanagawa, Japan
LEO Investigational Site
Yokohama, Kanagawa, Japan
LEO Investigational Site
Takatsuki-shi, Osaka, Japan
LEO Investigational Site
Koto-ku, Tokyo, Japan
LEO Investigational Site
Takaoka-shi, Toyama, Japan
LEO Investigational Site
Tokyo, , Japan
LEO Investigational Site
Wroclaw, Lower Silesian Voivodeship, Poland
LEO Investigational Site
Krakow, , Poland
LEO Investigational Site
Krakow, , Poland
LEO Investigational Site
Malbork, , Poland
LEO Investigational Site
Mikołów, , Poland
LEO Investigational Site
Wroclaw, , Poland
LEO Investigational Site
Cluj-Napoca, , Romania
LEO Investigational Site
Iași, , Romania
LEO Investigational Site
Timișoara, , Romania
LEO Investigational Site
Badalona, Barcelona, Spain
LEO Investigational Site
Alcobendas, , Spain
LEO Investigational Site
Alicante, , Spain
LEO Investigational Site
Barcelona, , Spain
LEO Investigational Site
Córdoba, , Spain
LEO Investigational Site
Madrid, , Spain
LEO Investigational Site
Zaragoza, , Spain
LEO Investigational Site
Edinburgh, , United Kingdom
LEO Investigational Site
Harrow, , United Kingdom
LEO Investigational Site
London, , United Kingdom
LEO Investigational Site
Manchester, , United Kingdom
LEO Investigational Site
Southampton, , United Kingdom
LEO Investigational Site
Walsall, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1286-0955
Identifier Type: OTHER
Identifier Source: secondary_id
2022-500777-14-00
Identifier Type: CTIS
Identifier Source: secondary_id
LP0145-2240
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.